MasterCard Inc vs Zoetis Inc — how do they compare? MasterCard Inc trades at $557.57 (market cap $491.83B), while Zoetis Inc trades at $72.37 (market cap $31.14B). The key difference: MasterCard Inc is far larger — about 15.8× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.81%). Which is the better fit depends on your goals.
| MA | ZTS | |
|---|---|---|
Market Cap | $491.83B | $31.14B |
Volume | 4,635,698 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $598.96 | $156.76 |
52-Week Low | $471.55 | $71.91 |
Enterprise Value | $504.86B | $38.70B |
Dividend Yield | 0.62% | 2.81% |
Signals from Pluang's Aura AI — not financial advice
Mastercard (MA) trades at $557.09, down 1.08% today, but maintains strong bullish technical momentum with consistent earnings beats and robust financial performance. The company reported Q2 2026 EPS of $5.04, beating expectations of $4.77, continuing a pattern of strong quarterly results. Revenue growth remains solid with 2025 revenue reaching $32.79 billion and net income of $14.97 billion, demonstrating the company's dominant position in payment processing. Recent institutional buying activity and positive analyst sentiment support the stock's upward trajectory.
Mastercard presents a compelling investment opportunity with strong fundamentals, consistent earnings growth, and bullish analyst consensus. The stock offers 18.6% upside to the consensus price target of $660.85. Key risks include competitive threats from emerging payment technologies and potential regulatory challenges in the financial services sector. The company's aggressive AI investments and global expansion initiatives position it well for continued growth, though investors should monitor payment industry disruption from stablecoins and digital payment innovations.
Zoetis (ZTS) trades at $74.86, up 3.03% today but facing bearish technical signals with 16 sell indicators. The company reported mixed Q2 2026 results, beating EPS estimates but missing revenue expectations, while cutting full-year guidance due to softer pet healthcare demand. Strong fundamentals include a 27.69% net margin and 64.91% ROE, though valuation metrics show a P/E of 12.29 and P/S of 3.41.
The stock presents a value opportunity with analyst consensus target of $94.90 (27% upside), but faces near-term headwinds from competitive pressures and class action lawsuits. Investors should weigh strong profitability against slowing growth in companion animal segments and technical bearishness.
Trailing returns across standard periods
Latest headlines on both assets
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →